Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + Cetuximab in Squamous NSCLC
NCT03717155Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Oct 2018
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of avelumab, KL-140 in squamous cell carcinoma of the lung (SCCL), sponsored by Merck KGaA. Started Oct 2018; status: completed.
02
Drugs
avelumabKL-140
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03717155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717155.